biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Deal Metrics

<< Previous

Bullboard Posts

Next >>

Post by barsaxon Dec 13, 2022 11:48am

282 Views

Post# 35168628

Deal Metrics

so Meditech issues 75900000 shares for $10M USD, OR $0.1318 USD per share. Meditech then turnsaround at issues .9556 of those shares for every BTI share, OR .9556 * $0.1318 USD = 0.1259 USD per BTI share. Converted at today's exchange rate of about 1.35 CDN per USD you get a $CDN price of ....you guessed it! 17 cents CDN per share....don't spend it all at once

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta